Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
41
HRTX Quote, Financials, Valuation and Earnings
Last price:
$1.35
Seasonality move
:
12.8%
Day range:
$1.26 - $1.32
52-week range:
$1.00 - $2.68
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.41x
P/B ratio:
33.94x
Volume:
3.2M
Avg. volume:
2.1M
1-year change:
-15.03%
Market cap:
$238.4M
Revenue:
$144.3M
EPS (TTM):
-$0.08
Analysts' Opinion
-
Consensus RatingHeron Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.50, Heron Therapeutics, Inc. has an estimated upside of 246.15% from its current price of $1.30.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $1.30.
Fair Value
-
According to the consensus of 2 analysts, Heron Therapeutics, Inc. has 246.15% upside to fair value with a price target of $4.50 per share.
HRTX vs. S&P 500
-
Over the past 5 trading days, Heron Therapeutics, Inc. has underperformed the S&P 500 by -5.21% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Heron Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Heron Therapeutics, Inc. has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Heron Therapeutics, Inc. reported revenues of $38.2M.
Earnings Growth
-
Heron Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Heron Therapeutics, Inc. reported earnings per share of -$0.10.
Enterprise value:
331.2M
EV / Invested capital:
2.13x
Price / LTM sales:
1.41x
EV / EBIT:
157.93x
EV / Revenue:
2.14x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-10.63x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
74.34x
Gross Profit (TTM):
$114.6M
Return On Assets:
-5.8%
Net Income Margin (TTM):
-8.76%
Return On Equity:
--
Return On Invested Capital:
-9.23%
Operating Margin:
-9.93%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $122.8M | $137.7M | $155.1M | $32.8M | $38.2M | |
| Gross Profit | $55M | $99.4M | $114.6M | $23.4M | $26.3M | |
| Operating Income | -$120.8M | -$25.9M | $2.1M | -$4.5M | -$3.8M | |
| EBITDA | -$117.8M | -$23.3M | $4.5M | -$3.9M | -$3.2M | |
| Diluted EPS | -$0.97 | -$0.18 | -$0.08 | -$0.03 | -$0.10 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $315.1M | $223.8M | $194M | $195.2M | $229.4M | |
| Total Assets | $352.4M | $272M | $229.2M | $220.8M | $249M | |
| Current Liabilities | $72.3M | $93.9M | $79.7M | $85.5M | $89.7M | |
| Total Liabilities | $233.5M | $249.5M | $257M | $260.8M | $234.1M | |
| Total Equity | $118.8M | $22.5M | -$27.8M | -$40M | $14.9M | |
| Total Debt | $164.5M | $155.4M | $177M | $175M | $139.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$98.8M | -$8.3M | -$30.2M | $3.4M | $1.3M | |
| Cash From Investing | $28.9M | -$1.5M | $32.9M | $4M | $11.9M | |
| Cash From Financing | $54.3M | $716K | $14.6M | $14K | $13.4M | |
| Free Cash Flow | -$100.5M | -$9.6M | -$31.1M | $2.9M | $1.3M | |
HRTX
Sector
Market Cap
$238.4M
$27.9M
Price % of 52-Week High
48.51%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-9.21%
-1.49%
1-Year Price Total Return
-15.03%
-16.66%
Beta (5-Year)
1.340
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.34
200-day SMA
Sell
Level
$1.69
Bollinger Bands (100)
Buy
Level
1.14 - 1.44
Chaikin Money Flow
Buy
Level
10.1M
20-day SMA
Buy
Level
$1.26
Relative Strength Index (RSI14)
Buy
Level
54.92
ADX Line
Sell
Level
26.5
Williams %R
Neutral
Level
-43.75
50-day SMA
Buy
Level
$1.21
MACD (12, 26)
Buy
Level
0.06
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
5.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.9426)
Sell
CA Score
(Annual)
Level (-3.4218)
Buy
Beneish M-Score
(Annual)
Level (-2.2858)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (8.3906)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in Cary, NC.
Stock Forecast FAQ
In the current month, HRTX has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HRTX average analyst price target in the past 3 months is $4.50.
-
Where Will Heron Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Heron Therapeutics, Inc. share price will rise to $4.50 per share over the next 12 months.
-
What Do Analysts Say About Heron Therapeutics, Inc.?
Analysts are divided on their view about Heron Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Heron Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Heron Therapeutics, Inc.'s Price Target?
The price target for Heron Therapeutics, Inc. over the next 1-year time period is forecast to be $4.50 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HRTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Heron Therapeutics, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of HRTX?
You can purchase shares of Heron Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Heron Therapeutics, Inc. shares.
-
What Is The Heron Therapeutics, Inc. Share Price Today?
Heron Therapeutics, Inc. was last trading at $1.35 per share. This represents the most recent stock quote for Heron Therapeutics, Inc.. Yesterday, Heron Therapeutics, Inc. closed at $1.30 per share.
-
How To Buy Heron Therapeutics, Inc. Stock Online?
In order to purchase Heron Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get HRTX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
HRTX
Sector
P/E ratio
--
23.85x
PEG ratio
--
-0.01x
P/B ratio
33.94x
1.81x
Price / LTM sales
1.41x
1.58x
Growth Metrics
HRTX
Sector
Revenue growth
16.47%
4.62%
Earnings growth
-223.98%
10.7%
Revenue (5-year growth)
-0.23%
6.5%
Earnings forecast
-$0.01
-$0.21
Profitability
HRTX
Sector
Profitability FY 2024
$105.6M
$3.6M
Return on invested capital
-9.23%
-31.87%
Return on assets
-5.8%
-28.18%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Feb
3
Balance Sheet
HRTX
Sector
Total cash
$55.5M
$26.4M
Short term investments
$33.5M
$25.7M
Total assets
$233.1M
$76.9M
Long term debt
$139.7M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 22
Lamb Weston Holdings, Inc. [LW] is down 2.59% over the past day.
Buy
54
BMRN alert for Dec 22
BioMarin Pharmaceutical, Inc. [BMRN] is down 3.03% over the past day.
Buy
82
RKLB alert for Dec 22
Rocket Lab Corp. [RKLB] is up 9.97% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
